Cancer to Cataracts: The Mechanistic Impact of Aldo-Keto Reductases in Chronic Diseases

Overview

Journal Yale J Biol Med

Specialty Biology

Date 2024 Jul 1

PMID 38947111

Authors

Anirudh P Shanbhag

Purnendu Bhowmik

Affiliations

Soon will be listed here.

Abstract

Aldo-keto reductases (AKRs) are a superfamily of promiscuous enzymes that have been chiseled by evolution to act as catalysts for numerous regulatory pathways in humans. However, they have not lost their promiscuity in the process, essentially making them a double-edged sword. The superfamily is involved in multiple metabolic pathways and are linked to chronic diseases such as cataracts, diabetes, and various cancers. Unlike other detoxifying enzymes such as cytochrome P450s (CYP450s), short-chain dehydrogenases (SDRs), and medium-chain dehydrogenases (MDRs), that participate in essential pathways, AKRs are more widely distributed and have members with interchangeable functions. Moreover, their promiscuity is ubiquitous across all species and participates in the resistance of pathogenic microbes. Moreover, the introduction of synthetic substrates, such as synthetic molecules and processed foods, results in unwanted "toxification" due to enzyme promiscuity, leading to chronic diseases.

References

Jin Y . Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: implications for the pharmacological effects of inhaled corticosteroids. Chem Biol Interact. 2011; 191(1-3):234-8. PMC: 3100382. DOI: 10.1016/j.cbi.2011.01.019. View

Zhou W, Wang Z, Mo H, Zhao Y, Li H, Zhang H . Thymol Mediates Bactericidal Activity against by Targeting an Aldo-Keto Reductase and Consequent Depletion of NADPH. J Agric Food Chem. 2019; 67(30):8382-8392. DOI: 10.1021/acs.jafc.9b03517. View

Chang Q, Harter T, Rikimaru L, Petrash J . Aldo-keto reductases as modulators of stress response. Chem Biol Interact. 2003; 143-144:325-32. DOI: 10.1016/s0009-2797(02)00216-8. View

Penning T . The aldo-keto reductases (AKRs): Overview. Chem Biol Interact. 2014; 234:236-46. PMC: 4388799. DOI: 10.1016/j.cbi.2014.09.024. View

Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X . Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int J Mol Sci. 2021; 22(23). PMC: 8657965. DOI: 10.3390/ijms222312808. View

Chen M, Drury J, Penning T . Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1). Steroids. 2011; 76(5):484-90. PMC: 3056882. DOI: 10.1016/j.steroids.2011.01.003. View

Pastel E, Pointud J, Volat F, Martinez A, Lefrancois-Martinez A . Aldo-Keto Reductases 1B in Endocrinology and Metabolism. Front Pharmacol. 2012; 3:148. PMC: 3410611. DOI: 10.3389/fphar.2012.00148. View

Kaltenbach M, Emond S, Hollfelder F, Tokuriki N . Functional Trade-Offs in Promiscuous Enzymes Cannot Be Explained by Intrinsic Mutational Robustness of the Native Activity. PLoS Genet. 2016; 12(10):e1006305. PMC: 5065130. DOI: 10.1371/journal.pgen.1006305. View

Ji Q, Aoyama C, Nien Y, Liu P, Chen P, Chang L . Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res. 2004; 64(20):7610-7. DOI: 10.1158/0008-5472.CAN-04-1608. View

10.

Huang Q, Cao J, Zhou Y, Huang J, Gong H, Zhang H . Aldo-keto Reductase-Like Protein Involved in Antioxidant and Anti-parasite Response. Front Microbiol. 2017; 8:2006. PMC: 5641555. DOI: 10.3389/fmicb.2017.02006. View

11.

Huang S, Palla S, Ruzycki P, Varma R, Harter T, Reddy G . Aldo-keto reductases in the eye. J Ophthalmol. 2010; 2010:521204. PMC: 2902055. DOI: 10.1155/2010/521204. View

12.

Romero P, Wagg J, Green M, Kaiser D, Krummenacker M, Karp P . Computational prediction of human metabolic pathways from the complete human genome. Genome Biol. 2005; 6(1):R2. PMC: 549063. DOI: 10.1186/gb-2004-6-1-r2. View

13.

Mantel A, Carpenter-Mendini A, VanBuskirk J, Pentland A . Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. Exp Dermatol. 2014; 23(8):573-8. PMC: 4125433. DOI: 10.1111/exd.12468. View

14.

Morikawa Y, Kezuka C, Endo S, Ikari A, Soda M, Yamamura K . Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10. Chem Biol Interact. 2015; 230:30-9. DOI: 10.1016/j.cbi.2015.02.005. View

15.

Manikandan P, Nagini S . Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets. 2017; 19(1):38-54. DOI: 10.2174/1389450118666170125144557. View

16.

Shanbhag A, Rajagopal S, Ghatak A, Katagihallimath N, Subramanian R, Datta S . A curated list of targeted optimized promiscuous ketoreductases (TOP-K). Biochem J. 2023; 480(13):975-997. DOI: 10.1042/BCJ20230051. View

17.

Novotna R, Wsol V, Xiong G, Maser E . Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008; 181(1):1-6. DOI: 10.1016/j.toxlet.2008.06.858. View

18.

Persson B, Hedlund J, Jornvall H . Medium- and short-chain dehydrogenase/reductase gene and protein families : the MDR superfamily. Cell Mol Life Sci. 2008; 65(24):3879-94. PMC: 2792335. DOI: 10.1007/s00018-008-8587-z. View

19.

Tian Y, Zhao L, Zhang H, Liu X, Zhao L, Zhao X . AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol. 2014; 9:42. PMC: 3939640. DOI: 10.1186/1746-1596-9-42. View

20.

Endo S, Matsunaga T, Nishinaka T . The Role of AKR1B10 in Physiology and Pathophysiology. Metabolites. 2021; 11(6). PMC: 8224097. DOI: 10.3390/metabo11060332. View